



FOR IMMEDIATE RELEASE

## GlobeImmune Promotes Jeffrey Dekker to Vice President of Finance

**LOUISVILLE, Colo., Aug. 31, 2011** - GlobeImmune Inc. announced today the promotion of Jeffrey Dekker to Vice President of Finance. Mr. Dekker previously served as Controller and Senior Director Finance at GlobeImmune since joining the company in 2006.

Before joining GlobeImmune, Mr. Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.

### About GlobeImmune

GlobeImmune Inc. is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate cancer cells and/or virally infected cells. The company's lead infectious disease product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). The company's lead oncology programs, GI-4000 and GI-6207, target cancers caused by mutated versions of the Ras oncoprotein and CEA expressing tumors, respectively. GI-4000 is being investigated in clinical trials for the treatment of cancers expressing mutated Ras, including non-small cell lung cancer, pancreatic cancer and colorectal cancer. GI-6207 is being evaluated in clinical trials in patients with CEA expressing tumors. In July 2008, GlobeImmune signed a Cooperative Research and Development Agreement (CRADA) with NCI and the National Institutes of Health to jointly develop multiple product candidates intended to treat a variety of cancers. In May 2009, the company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company's website at [www.globeimmune.com](http://www.globeimmune.com).

#### MEDIA CONTACT:

Matt Middleman, M.D.  
Russo Partners LLC  
T: 212-845-4272  
M: 917-734-0324  
[matt.middleman@russopartnersllc.com](mailto:matt.middleman@russopartnersllc.com)

#### GLOBEIMMUNE CONTACT:

Timothy C. Rodell M.D.  
President & Chief Executive Officer  
1450 Infinite Drive  
Louisville CO 80027  
email: [info@globeimmune.com](mailto:info@globeimmune.com)  
phone: 303-625-2820

